James Murdoch steps down from GSK board
pharmafile | January 27, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | GSK, James Murdoch
GlaxoSmithKline has announced that after nine years with the firm, Sir Crispin Davis, Sir Robert Wilson and Larry Culp will stand down from the board.
In addition, the UK firm said that James Murdoch has decided not to stand for re-election.
Sir Christopher Gent, chairman of GSK, said: “James Murdoch has decided to stand down from the board with effect from this year’s AGM.
“James has taken this decision to focus on his current duties as non-executive chairman of BSkyB, and following his decision to relocate to the US, as chairman and chief executive, International, of News Corporation.
“On behalf of the board, I would like to thank James for the very strong contribution he has made since he was appointed in 2009 and wish him well.”
Tom de Swaan will now succeed Sir Crispin Davis as chairman of the remuneration committee with effect from 1 January 2013.
From the same date Judy Lewent will succeed Tom de Swaan as chair of the audit and risk committee, and Sir Deryck Maughan will succeed Sir Robert Wilson as senior independent on-executive director.
Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis
GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination …





